# ScoreItem: DHEA-S - Mulheres (30-39 anos)

**ID:** `c77cedd3-2800-7363-97a8-7dd8f7a8d087`
**FullName:** DHEA-S - Mulheres (30-39 anos) (Exames - Laboratoriais)
**Unit:** ¬µg/dL
**Gender:** female
**Age Min:** 30 anos
**Age Max:** 39 anos

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 9 artigos
- Avg Similarity: 0.680

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `c77cedd3-2800-7363-97a8-7dd8f7a8d087`.**

```json
{
  "score_item_id": "c77cedd3-2800-7363-97a8-7dd8f7a8d087",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** DHEA-S - Mulheres (30-39 anos) (Exames - Laboratoriais)
**Unidade:** ¬µg/dL
**G√™nero:** female
**Faixa Et√°ria:** 30-39 anos

**30 chunks de 9 artigos (avg similarity: 0.680)**

### Chunk 1/30
**Article:** Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women (2025)
**Journal:** Clinical Endocrinology
**Section:** abstract | **Similarity:** 0.745

Diretriz cl√≠nica da Society for Endocrinology para avalia√ß√£o de excesso androg√™nico em mulheres. DHEA-S s√©rico √© a medida mais confi√°vel de produ√ß√£o adrenal de andr√≥genos, particularmente √∫til na transi√ß√£o perimenop√°usica. Aproximadamente 25% da produ√ß√£o androg√™nica ocorre nas adrenais em mulheres pr√©-menop√°usicas, aumentando para 100% na p√≥s-menopausa. Decl√≠nio de DHEA-S inicia aos 30 anos devido √† involu√ß√£o da zona reticular adrenal.

---

### Chunk 2/30
**Article:** Ritmo Circadiano Eixo HPA - Parte XI (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.728

omens, a dose m√©dia de DHEA varia entre 25 e 50 miligramas.
- Notavelmente, uma dose de 50 mg de DHEA, geralmente associada a homens, tamb√©m √© indicada para mulheres com o objetivo de melhorar o humor, o bem-estar e a fun√ß√£o sexual.
**A S√≠ndrome da Fadiga Cr√¥nica (SFC) afeta predominantemente adultos jovens entre 20 e 40 anos, com uma preval√™ncia duas a tr√™s vezes maior em mulheres do que em homens.**
- A SFC √© mais comum em adultos na faixa et√°ria de 20 a 40 anos.
- As mulheres s√£o diagnosticadas com SFC de duas a tr√™s vezes mais frequentemente do que os homens, indicando uma clara disparidade de g√™nero na preval√™ncia da condi√ß√£o.
### Achados Adicionais Chave
- A ideia de que as gl√¢ndulas adrenais s√£o as primeiras a mostrar sinais de cansa√ßo foi introduzida em uma publica√ß√£o de 1921.

---

### Chunk 3/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.720

dose dehydroepiandrosterone affects
behavior in hypopituitary androgen-deficient women: a placebocontrolled trial. J Clin
Endocrinol Metab 2002;87:2046
144. van Thiel SW, Romijn JA, Pereira AM, et al. Effects of dehydroepiandrostenedione,
superimposed on growth hormone substitution, on quality of life and insulin-like growth factor
I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-
over trial. J Clin Endocrinol Metab 2005;90:3295‚Äì303
145. Lovas K, Gebre-Medhin G, Trovik T, et al. Replacement of dehydroepiandrosterone in
adrenal failure: no benefit for subjective health status and sexuality in a 9-month randomized
parallel group clinical trial. J Clin Endocrinol Metab 2003;88:1112‚Äì8
146. Avis NE, Brockwell S, Randolph Jr JF, et al. Longitudinal changes in sexual functioning
as women transition through menopause: results from the Study of Women‚Äôs Health Across
the Nation. Menopause 2009;16:442‚Äì52
147.

---

### Chunk 4/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.713

Stanczyk FZ, Bairey Merz CN. DHEA-S levels and
cardiovascular disease mortality in postmenopausal women: Results from the National
Institutes of Health‚ÄìNational Heart, Lung, and Blood Institute (NHLBI)-sponsored Women‚Äôs
Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 2010;95:4985‚Äì4992
204. Christiansen JJ, Andersen NH, S√∏rensen KE, Pedersen EM, Bennett P, Andersen M,
Christiansen JS, J√∏rgensen JO, Gravholt CH. Dehydroepiandrosterone substitution in
female adrenal failure: no impact on endothelial function and cardiovascular parameters
despite normalization of androgen status. Clin Endocrinol 2007;66:426‚Äì433
205. Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of
oral DHEA therapy for postmenopausal women. Maturitas 2009;63:240‚Äì245
206. Cleary MP, Zisk JF. Anti-obesity effect of two different levels of
dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes
1986;10:193‚Äì204
207.

---

### Chunk 5/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XVII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.711

do ao bloqueio da enzima 5-alfa-redutase.
    *   16-hidroxiestrona e 4-hidroxiestrona: Elevadas, indicando desvio do metabolismo hormonal.
    *   Beta-pregnanediol e Alfa-pregnanediol: N√≠veis baixos, indicando deple√ß√£o e estresse.
*   **Exames de Sangue Anteriores:** A testosterona s√©rica estava em um n√≠vel normal-baixo.
**Achados Gerais e de Estudos (Apresenta√ß√£o M√©dica):**
*   **Minoxidil:** Eficaz em cerca de 33% dos casos para queda de cabelo. A efic√°cia depende do gene SULT1A1; um polimorfismo comum neste gene leva √† falta de resposta.
*   **Finasterida e Dutasterida:**
    *   **Mecanismo:** Inibem a enzima 5-alfa-redutase, que converte testosterona em DHT. A dutasterida √© mais potente, inibindo os tipos 1 e 2 da enzima.
    *   **S√≠ndrome P√≥s-Finasterida:** Associa√ß√£o de sintomas sexuais, f√≠sicos e psicol√≥gicos que se desenvolvem durante ou ap√≥s o uso e persistem ap√≥s a descontinua√ß√£o.

---

### Chunk 6/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 01 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.702

reavaliar a cada 6‚Äì8 semanas, checar SHBG, estradiol, DHT se pertinente) para padronizar seguimento.
### 8. DHEA (prasterona): papel, prescri√ß√£o e diferen√ßas entre sexos
- DHEA/DHEA-S: pr√≥-horm√¥nio, n√£o considerado horm√¥nio pleno; decl√≠nio com a idade, especialmente adrenal.
- Em mulheres, pode estimular horm√¥nios subsequentes; em homens, n√£o costuma ter fun√ß√£o robusta para estimular outros horm√¥nios.
- No Brasil, prescri√ß√£o como prasterona; estudos principalmente com comprimido; creme seria mais fisiol√≥gico, por√©m menos estudado; ambas formas poss√≠veis.
- Doses mulheres: baixas (10‚Äì15 mg) e monitorar porque pode elevar horm√¥nios indesejados; utilidade em infertilidade/autoimunes com dose b√°sica.
- Conceito de ‚Äúdesgaste‚Äù glandular ao longo da vida aplic√°vel √†s adrenais.
> **Sugest√µes de IA**
> - Organiza√ß√£o: Voc√™ delimitou bem diferen√ßas por sexo; inclua crit√©rios claros de quando considerar prasterona (indica√ß√µes vs quando evitar).

---

### Chunk 7/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** results | **Similarity:** 0.690

Windahl SH, Wu J, et al. Dehydroepiandrosterone supplementation results in varying tissue-speciÔ¨Åc levels of dihydrotestosterone in male mice. Endocrinology. 2022;163(12):163. 12. Jankowski CM, Wolfe P, Schmiege SJ, Nair KS, Khosla S, Jensen M, et al. Sex-speciÔ¨Åc eÔ¨Äects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: a pooled analysis of four clinical trials. Clin Endocrinol. 2019;90(2):293¬ñ300.

Page 12 of 13Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
 13. Yuan H, Ou Q, Ma Y, Chen R, Wu H, Li F, et al. EÔ¨Éciency of DHEA on diminished ovarian reserve patients undergoing IVF-ET based on ultrasonography. Int J Clin Exp Med. 2016;9:14337¬ñ44. 14. ScheÔ¨Äers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehy-droepiandrosterone for women in the perior postmenopausal phase. Cochrane Datab Syst Rev. 2015(1). 15. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM.

---

### Chunk 8/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.690

208
]. In humans studies, however, the results  are
rather inconsistent. In some studies, the lower levels of DHEA seen with aging have been
associated with impaired glucose tolerance, insulin resistance and diabetes [
212
-
215
], while
in another [
216
] exactly the opposite relation was shown as higher levels of DHEA were
13

associated with impaired glucose tolerance and diabetes mellitus in post-menopausal
women. The truth regarding DHEA/DHEAS and insulin resistance and its associated
conditions gets even more complicated considering conflicting results from interventional
studies with DHEA replacement. Thus, an ameliorating effect of long-term treatment with
DHEA on insulin resistance was described in a group of middle-aged hypo-adrenal women
treated with DHEA [
217
], but also in groups of elderly men [
97
] and postmenopausal women
[
97,217-220
] replaced with DHEA.

---

### Chunk 9/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** results | **Similarity:** 0.688

was further supported by the results of Egger¬ís regression test.Discussionis meta-analysis of randomized controlled trials (RCTs) evaluated the eÔ¨Äects of dehydroepiandrosterone (DHEA) supplementation on testosterone and estradiol levels in postmenopausal women. Our analysis of 21 RCTs revealed that DHEA supplementation signiÔ¨Åcantly increased both testosterone and estradiol concentrations, although substantial heterogeneity was observed across the included trials.Our Ô¨Åndings indicate that DHEA is particularly eÔ¨Äec-tive in elevating testosterone levels when administered at dosages  50 mg/day. Additionally, a marked increase in estradiol levels was noted among participants aged  60 years receiving the same dosage. ese Ô¨Åndings 
Fig. 2 Forest plot of the randomized controlled trials investigating the eÔ¨Äect of dehydroepiandrosterone (DHEA) supplementation on serum estradiol concentrations

Page 9 of 13
Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
Fig.

---

### Chunk 10/30
**Article:** Ritmo Circadiano Eixo HPA - Parte XI (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.684

mente.
    - No Brasil, prescreve-se prasterona.
    - Doses m√©dias: 10‚Äì15 mg para mulheres e 25‚Äì50 mg para homens.
    - Em homens, DHEA n√£o se mostrou eficaz para aumentar horm√¥nios esteroides como precursor.
    - Avalia√ß√£o laboratorial pelo S-DHEA (sulfato de DHEA), forma de reserva no sangue.
### 3. S√≠ndrome da Fadiga Cr√¥nica (SFC)
*   **Defini√ß√£o e Sintomas**
    - Fadiga intensa, de causa desconhecida, persistente, limitante e que n√£o melhora com descanso.
    - Frequentemente confundida com depress√£o, astenia (melhora com sono) e fraqueza (perda de for√ßa muscular).
    - Sintomas associados: dores articulares e musculares, cefaleia, ansiedade, sintomas depressivos, dist√∫rbios cognitivos e do sono, intoler√¢ncia a exerc√≠cios.
    - Classifica√ß√£o por tempo: recente (<1 m√™s), prolongada (>1 m√™s), cr√¥nica (>6 meses).
*   **Diagn√≥stico e Etiologia**
    - Dificuldade diagn√≥stica por desconhecimento etiol√≥gico e quantifica√ß√£o dos sintomas.

---

### Chunk 11/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.683

late postmenopause. Gynecolog Endocrinol 2000;14:342‚Äì363
139. Panjari M, Davis SR. DHEA therapy for women: effect on sexual function andwellbeing.
Human Reprod Update 2007;13:239‚Äì48 
140. Arlt W, Callies F, van Vlijmen JC, et al.. Dehydroepiandrosterone replacement in
women with adrenal insufficiency. N Engl J Med 1999; 341: 1013‚Äì1020
141. Mortola JF, Yen SS.The effects of oral dehydroepiandrosterone on endocrine-metabolic
parameters in postmenopausal women. J Clin Endocrinol Metab 1990; 71: 696‚Äì704
142. Wolf OT, Neumann O, Hellhammer DH, et al..Effects of a two-week physiological
dehydroepiandrosterone substitution on cognitive performance and well-being in healthy
elderly women and men. J Clin Endocrinol Metab 1997; 82: 2363‚Äì2367
143. Johannsson G, Burman P, Wiren L, et al. Low dose dehydroepiandrosterone affects
behavior in hypopituitary androgen-deficient women: a placebocontrolled trial. J Clin
Endocrinol Metab 2002;87:2046
144.

---

### Chunk 12/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 01 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.682

80 anos com testosterona de 500-600, sugerindo que seus n√≠veis de pico na juventude poderiam ter sido muito mais altos (ex: 1.500).
*   **Decl√≠nio Hormonal Feminino e DHEA**
    - Mulheres tamb√©m experimentam um decl√≠nio na testosterona, que √© produzida pelos ov√°rios e adrenais. A queda pode ser menos linear que nos homens, pois a produ√ß√£o adrenal pode ser preservada.
    - O DHEA (deidroepiandrosterona), um pr√≥-horm√¥nio precursor, diminui nitidamente com a idade, indicando um "desgaste" da gl√¢ndula adrenal.
    - A prescri√ß√£o de DHEA (prasterona no Brasil) √© feita em comprimidos (forma mais estudada) ou creme (forma mais fisiol√≥gica). Doses para mulheres s√£o menores (10-15mg) para evitar convers√µes indesejadas. Para homens, sua fun√ß√£o como estimulador de outros horm√¥nios √© menos estabelecida.
### 4.

---

### Chunk 13/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** results | **Similarity:** 0.680

sely associated with glucose concentration in the medium. J Steroid Biochem Mol Biol. 2000;75(2¬ñ3):159¬ñ66. 8. De Menezes KJ, Peixoto C, Nardi AE, Carta MG, Machado S, Veras AB. Dehydroepiandrosterone, its sulfate and cognitive functions. Clin Pract Epidemiol Ment Health CP EMH. 2016;12:24. 9. Ma Y, Fan X, Han J, Cheng Y, Zhao J, Fang W, et al. Critical illness and sex hormones: response and impact of the hypothalamic¬ñpituitary¬ñgonadal axis. Therap Adv Endocrinol Metab. 2025;16:20420188251328190. 10. Kawakita T, Yasui T, Yoshida K, Matsui S, Iwasa T. Correlations of andros-tenediol with reproductive hormones and cortisol according to stages during the menopausal transition in Japanese women. J Steroid Biochem Mol Biol. 2021;214: 106009. 11. Colld√©n H, Nilsson ME, Norl√©n A-K, Landin A, Windahl SH, Wu J, et al. Dehydroepiandrosterone supplementation results in varying tissue-speciÔ¨Åc levels of dihydrotestosterone in male mice. Endocrinology. 2022;163(12):163. 12.

---

### Chunk 14/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.678

arch on Menopause in the 1990s. WHO Technical Report Series
1996;no. 866: 4
30. Lasley B, Crawford S, Laughlin G, et al. Circulating Dehydroepiandrosterone Levels in
Women with Bilateral Salpingo-Oophorectomy during the Menopausal Transition.
Menopause. 2011; 18:494‚Äì498
31. Crawford S, Santoro N, Laughlin GA, et al. Circulating Dehydroepiandrosterone Sulfate
Concentrations during the Menopausal Transition. J Clin Endocrinol Metab. 2009; 94:2945‚Äì
2951
32. Randolph JF Jr, Sowers M, Gold EB, et al. Reproductive hormones in the early
menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin
Endocrinol Metab. 2003; 88:1516‚Äì1522
22

33. B. L. Lasley, S. Crawford, and D.S. McConnell.Adrenal Androgens and the Menopausal
Transition. Obstet Gynecol Clin North Am. 2011 ; 38: 467‚Äì475
34. Parker, LN (1991). "Adrenarche".
 
Endocrinology and metabolism clinics of North
America
 
20
 
: 71‚Äì83
35. Liu D, Dillon JS.

---

### Chunk 15/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.678

levels [
160
], making the relation between
DHEA/DHEAS and depression even more confusing.
Several interventional studies have shown that DHEA replacement may improve negative
and depressive symptoms [
134
,
135
,
161
-
163
]
. 
In women with adrenal insufficiency, in
11

particular, oral DHEA replacement significantly improved the overall well-being, as well as
scores for depression and anxiety [
108
]; similar results were found in the management of the
negative symptoms of schizophrenia
 [
163
]. 
Most recent placebo-controlled randomized
trials, however, failed to demonstrate a beneficial effect of DHEA therapy on mood, quality of
life, perceptions of physical and emotional health, and life satisfaction in postmenopausal
women [
73
,
75
,
76
]. Thus the therapeutic role of DHEA on mood disorders remains unclear.
3d.

---

### Chunk 16/30
**Article:** S√≠ndrome dos Ov√°rios Polic√≠sticos - Parte II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.675

m paciente espec√≠fico; o conte√∫do descreve orienta√ß√£o cl√≠nica geral sobre SOP, incluindo:
  - Dificuldade de controle metab√≥lico apesar de exerc√≠cios/dieta.
  - Irregularidade menstrual e anovula√ß√£o.
  - Hiperandrogenismo (acne, hirsutismo).
  - Ansiedade, irritabilidade, dificuldade de sono.
  - Infertilidade, potencial risco CV associado √† hiper-homocisteinemia.
## Objetivo:
- Crit√©rios diagn√≥sticos (Roterd√£): requer 2 de 3 para SOP:
  - Irregularidade menstrual/anuvolu√ß√£o cr√¥nica (oligomenorreia, amenorreia).
  - Hiperandrogenismo cl√≠nico/biol√≥gico (acne, hirsutismo; viriliza√ß√£o √© incomum e sugere tumores/andr√≥genos ex√≥genos).
  - Ov√°rios polic√≠sticos na ultrassonografia (n√£o obrigat√≥rio).
- Escalas/avalia√ß√µes:
  - Ferriman-Gallwey (hirsutismo): ‚â•6 (geral); em descend√™ncia asi√°tica, ‚â•4.
- Exames laboratoriais para diferenciais:
  - Prolactina (hiperprolactinemia).
  - 17-OHP (HAC n√£o cl√°ssica).
  - TSH, T4 (¬± T3) para disfun√ß√£o tireoidiana.

---

### Chunk 17/30
**Article:** Ritmo Circadiano Eixo HPA - Parte XI (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.675

e DHEA (prasterona), sobretudo para mulheres com doen√ßas autoimunes. Destaca-se tamb√©m a vulnerabilidade das adrenais a toxinas e medicamentos, devido ao alto fluxo sangu√≠neo, e a import√¢ncia dos antioxidantes na sua prote√ß√£o.
## üîñ Pontos de Conhecimento
### 1. Controv√©rsia sobre a Nomenclatura "Fadiga Adrenal"
*   **Pol√™mica da Nomenclatura vs. Import√¢ncia Cl√≠nica**
    - A discuss√£o sobre "fadiga adrenal" √© antiga, com publica√ß√µes de 1921 j√° mencionando "sinais de cansa√ßo" nas suprarrenais.
    - Autores como James Wilson e Michael Lamb popularizaram o termo.
    - O instrutor considera irrelevante a pol√™mica sobre o nome; o foco deve ser identificar e tratar a condi√ß√£o subjacente.
    - Revis√£o sistem√°tica brasileira concluiu que "fadiga adrenal" como entidade n√£o existe, pois a gl√¢ndula n√£o fadiga.
    - Negar o termo n√£o invalida a import√¢ncia de avaliar e tratar a disfun√ß√£o do eixo HPA.

---

### Chunk 18/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 04 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.669

itos.
- Queda de cabelo acentuada.
- TPM muito intensa em mulheres.
## Objetivo:
Aula, n√£o consulta. Achados objetivos/patol√≥gicos gerais:
- Testosterona em homens diminui com a idade; n√≠veis <400 ng/dL s√£o considerados baixos.
- Baixa testosterona associada a maior ocorr√™ncia de obesidade, hipertens√£o, hiperlipidemia, alergias e diabetes.
- Alta preval√™ncia de hipogonadismo hipogonadotr√≥fico (falta de comando central) em homens obesos.
- Obesidade aumenta atividade da aromatase, resist√™ncia √† insulina e apneia do sono, levando a hipogonadismo hipotal√¢mico.
- Obesidade pode elevar a temperatura escrotal, piorar produ√ß√£o de testosterona e levar a oligospermia/azoospermia.
- Exames de sangue para horm√¥nios livres (ex.: testosterona livre) s√£o imprecisos no Brasil, pois laborat√≥rios calculam em vez de medir diretamente; ~80% dos horm√¥nios livres aderem √†s hem√°cias e s√£o removidos na centrifuga√ß√£o.

---

### Chunk 19/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** discussion | **Similarity:** 0.668

asures [
27]
.
Since DHEA is the main source of androgens in women, its age-related decline leads to a
corresponding decrease in the total androgen pool. Although there is actually no defined
level of androgen below which women can be said to be deficient, the decline of DHEA in
postmenopausal women would 
suggest
 they are ‚Äúdeficient‚Äù in both estrogens and androgens
[16]. The declining circulating levels of adrenal androgens with advancing age have been
related to clinical symptoms and disorders (see below).
In the last few years, the concept that adrenal androgen production gradually declines with
advancing age has changed following the analysis of the longitudinal data collected in the
Study of Women‚Äôs Health Across the Nation (SWAN) [28].

---

### Chunk 20/30
**Article:** S√≠ndrome dos Ov√°rios Polic√≠sticos - Parte II (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.668

1.000‚Äì2.000 mg/dia com enhancers de biodisponibilidade.
  - Coenzima Q10: suporte √† foliculog√™nese e resposta a indutores.
## Diagn√≥stico Principal:
- Avalia√ß√£o: SOP em discuss√£o, com foco em resist√™ncia √† insulina, hiperandrogenismo, irregularidade menstrual, riscos e impactos de COCs, e estrat√©gias de manejo metab√≥lico e reprodutivo. Conte√∫do educacional; sem confirma√ß√£o em paciente espec√≠fico.
- Diagn√≥stico Suspeito: Nenhum no momento.
## Plano:
- Prescri√ß√£o:
  - Inserir de acordo com o caso individual.
  - Op√ß√µes discutidas:
    - Metformina XR at√© 1.500 mg/dia (avaliar renal, B12/B6/folato).
    - Mio-inositol 2 g + √°cido f√≥lico 200 mcg, 2x/dia; considerar alfa-lactoalbumina 50 mg, 2x/dia.
    - Progesterona micronizada oral em esquema c√≠clico: 200 mg/dia por 10‚Äì14 dias do ciclo (ex.: dias 15‚Äì24); monitorar humor/sono.
    - Antiandrog√™nios em sintomas: espironolactona, finasterida; considerar Serenoa repens 400 mg em acne/hirsutismo.

---

### Chunk 21/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 01 (2024)
**Journal:** Pos Graduacao MFI
**Section:** methods | **Similarity:** 0.665

adrenais.
> **Sugest√µes de IA**
> - Organiza√ß√£o: Voc√™ delimitou bem diferen√ßas por sexo; inclua crit√©rios claros de quando considerar prasterona (indica√ß√µes vs quando evitar).
> - M√©todos: Uma tabela de ‚Äúdose inicial, forma, monitoriza√ß√£o, poss√≠veis efeitos‚Äù tornaria a aplica√ß√£o cl√≠nica mais direta.
> - Clareza: Bom contraste entre comprimido vs creme; reforce com um protocolo de acompanhamento (ex.: revisar DHEA-S e sintomas ap√≥s 8‚Äì12 semanas).
> - Melhoria: Apresente um caso cl√≠nico feminino (p. ex., fadiga, baixa libido, infertilidade) para mostrar decis√£o e ajuste de DHEA.
## Perguntas dos Alunos
Nenhuma pergunta foi levantada pelos alunos.

---

### Chunk 22/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.663

/ doi. org/ 10. 1046/j. 1365- 2265. 1998. 00507.x. 38. Kudielka BM, Hellhammer J, Hellhammer DH, Wolf OT, Pirke KM, Varadi E, et al. Sex diÔ¨Äerences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a 2-week dehydroepiandrosterone treatment. J Clin Endocrinol Metab. 1998;83(5):1756¬ñ61. https:// doi. org/ 10. 1210/ jcem. 83.5. 4758. 39. Casson PR, Faquin LC, Stentz FB, Straughn AB, Andersen RN, Abra-ham GE, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril. 1995;63(5):1027¬ñ31. 40. Li Y, Ren J, Li N, Liu J, Tan SC, Low TY, et al. A dose-response and meta-analysis of dehydroepiandrosterone (DHEA) supplementation on testosterone levels: perinatal prediction of randomized clinical trials. Exp Gerontol. 2020;141: 111110. 41. Zhu Y, Qiu L, Jiang F, GƒÉman M-A, Abudoraehem OS, Okunade KS, et al.

---

### Chunk 23/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.663

oups of elderly men [
97
] and postmenopausal women
[
97,217-220
] replaced with DHEA. The DHEA dose used ranged between 25 and 100
mg/day 
per os
 and the duration of treatment varied between 3 and 12 months; in one study
transdermal DHEA was used [
220
]. Most other interventional studies addressing this issue,
failed to demonstrate any significant effect of DHEA on insulin resistance/sensitivity
[
73
,
94
,
105
,
108
,
111
,
112
,
143
,
205
,
221
-
224
] and so did 
a
 recent review of the available data
regarding use of DHEA in women with adrenal insufficiency [
77
]. Remarkably
, 
Mortola and
Yen [
140
] reported worsening insulin resistance with DHEA replacement in
postmenopausal
 
women; in this study however, the number of participants was small (n=6),
the duration of treatment short (28 days), and the DHEA dosage supraphysiological (1600
mg/day 
per os
). Puting together the above, the relation between DHEA and carbohydrate
metabolism is still uncertain.
3g.

---

### Chunk 24/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.662

ement
in healthy men with age-related decline of DHEA-S: Effects on fat distribution, insulin
sensitivity and lipid metabolism. Aging Male 2003; 6:151‚Äì156
27

108. Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio
B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: Effects on
body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol
Metab 2001;86:1968‚Äì 1972
109. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G.
Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab
1999;84:1527‚Äì1533
110. Percheron G, Hogrel JY, Denot-Ledunois S, Fayet G, Forette F, Baulieu EE, Fardeau
M, Marini JF. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-
year-old individuals on muscle function and cross-sectional area: A double-blind placebo-
controlled trial. Arch Int Med 2003;163:720‚Äì727
111.

---

### Chunk 25/30
**Article:** S√≠ndrome dos Ov√°rios Polic√≠sticos - Parte II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.659

; em descend√™ncia asi√°tica, ‚â•4.
- Exames laboratoriais para diferenciais:
  - Prolactina (hiperprolactinemia).
  - 17-OHP (HAC n√£o cl√°ssica).
  - TSH, T4 (¬± T3) para disfun√ß√£o tireoidiana.
  - Testosterona total/livre, DHEA-S (tumores secretores/uso ex√≥geno).
  - USG p√©lvica; RM/TC se suspeita de tumores.
  - S√≠ndrome de Cushing: cortisol salivar noturno ou teste de supress√£o com dexametasona 1 mg (se suspeita cl√≠nica).
- Achados cl√≠nicos gerais:
  - Irregularidade menstrual frequente; ciclos <21 dias, oligomenorreia >35 dias, amenorreia ‚â•3 meses ou <8 menstrua√ß√µes/ano.
  - Sangramento uterino anormal de causa ovulat√≥ria (n√£o estrutural) pode ocorrer.
  - Fen√≥tipo A (tr√™s crit√©rios presentes) com maior risco de complica√ß√µes metab√≥licas.

---

### Chunk 26/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.657

o DHEA supplementation.Biochemically, DHEA serves as a precursor to both estrogens and androgens. Once converted to DHEA sulfate in the liver, it undergoes further enzymatic trans-formation in peripheral tissues, where it contributes to the synthesis of active estrogens and androgens, includ-ing estradiol and testosterone [6].It is important to note that elevated levels of estradiol can have adverse eÔ¨Äects, such as stimulating the endo-metrium [27]. Consequently, prolonged high estradiol levels may increase the risk of developing endometrial carcinoma [49]. erefore, it is crucial to use low doses of DHEA to raise estradiol levels without overstimulating the endometrium [50]. In our review, subgroup analysis based on DHEA dosage showed that doses of 50 mg/day or higher signiÔ¨Åcantly increased estradiol levels.

---

### Chunk 27/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.654

ials investigating the eÔ¨Äect of dehydroepiandrosterone (DHEA) supplementation on serum estradiol concentrations

Page 9 of 13
Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
Fig. 3 Forest plot of the randomized controlled trials investigating the eÔ¨Äect of dehydroepiandrosterone (DHEA) supplementation on serum testosterone concentrations
Fig. 4 Funnel plot of the weighted mean diÔ¨Äerence (WMD) versus the standard error (s.e.) of the WMD

Page 10 of 13Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
are consistent with a previous meta-analysis by Li etal., which reported increased testosterone levels in partici-pants receiving > 50 mg/day of DHEA for  12 weeks, particularly among those under 60 years of age [40]. Sim-ilarly, Zhu etal. found that estradiol concentrations were signiÔ¨Åcantly increased in participants aged  60 years who received  50 mg/day of DHEA for  26 weeks [41].

---

### Chunk 28/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 08 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.653

avaliar: alimenta√ß√£o, intestino, zinco, homociste√≠na, folato, B12, ferritina, satura√ß√£o de transferrina, DHT sangu√≠neo e salivar, 3-alfa-diol, cortisol.
- Crit√©rio √©tico: se bloquear androg√™nios sistemicamente, discutir riscos (c√¢ncer a longo prazo, dem√™ncia, osteoporose, cardiovasculares, sarcopenia, depress√£o).
- Preferir estrat√©gias t√≥picas e moduladoras (ex.: serenoa repens/saw palmetto) quando poss√≠vel, com acompanhamento de n√≠veis livres (saliva).
> **Sugest√µes de IA**
> √ìtima defesa de uma avalia√ß√£o sist√™mica. Para tornar aplic√°vel, voc√™ poderia fornecer um ‚Äúpainel b√°sico de exames‚Äù em slide e uma √°rvore de decis√£o simplificada (ex.: ‚ÄúDHT livre alto + couro cabeludo inflamado ‚Üí priorizar anti-inflamat√≥rios e t√≥picos; ferritina <40 ng/mL ‚Üí repor ferro‚Äù). Considere um quadro comparando riscos/benef√≠cios de bloqueio sist√™mico versus t√≥pico.

---

### Chunk 29/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** discussion | **Similarity:** 0.652

ffect of Dehydroepiandrosterone
on Muscle Strength and Physical Function in Older Adults: A Systematic Review. J Am
Geriatr Soc 2011;59:997‚Äì1002
75. Kritz-Silverstein D, von M√ºhlen D, Gail A. Laughlin GA, Bettencourt R. Effects of
dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA
and well-ness (DAWN) trial. J Am Geriat Soc 2008;56:1292‚Äì8
76. Panjari M, Bell RJ, Jane F, et al..A randomized trial of oral DHEA treatment for sexual
function, well-being, and menopausal symptoms in postmenopausal women with low libido. J
Sex Med 2009; 6: 2579‚Äì2590
77. Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and metaanalysis of
randomized placebo-controlled trials of DHEA treatment effects on quality of life in women
with adrenal insufficiency.
J Clin Endocrinol Metab 2009;94:3676‚Äì81
78. Labrie F, Archer D, Bouchard C, et al.

---

### Chunk 30/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.650

K, Ouyang P.
Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin
Endocrinol Metab 2007;92:1289‚Äì1295
216. Barrett-Connor E, Ferrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate,
obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: The
Rancho Bernardo Study. J Clin Endocrinol Metab 1996;81:59‚Äì64
217. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on
insulin sensitivity and lipids in hypoadrenal women. Diabetes 2005;54:765‚Äì769
218. Lasco A, Frisina N, Morabito N, et al. Metabolic effects of dehydroepiandrosterone
replacement therapy in postmenopausal women. Eur J Endocrinol 2001;145:457‚Äì61
219. G√≥mez-Santos C, Larqu√© E, Granero E, Hern√°ndez-Morante J, Garaulet M.
Dehydroepiandrosterone-sulphate replacement improves the human plasma fatty acid profile
in plasma of obese women. Steroids 2011;76:1425‚Äì1432
220. Diamond P, Cusan L, Gomez JL, Belanger A, Labrie F.

---

